BURBANK, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC-BB:QNTA), announced today that the Company submitted the final clinical trial data to the Dominican Republic (“DR”) Ministry of Health (“MoH”) for approval of the Company’s product, Escozine, as a COVID-19 treatment. The product, which is registered as an alternative oncological medicine in the DR, has shown to be effective against variations of the SARS-CoV-2 virus.
Medolife Rx Submits Final Clinical Trial Data for Escozine Approval as a COVID-19 Treatment in The Dominican Republic
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Apple%20products%20on%20desk%20by%20Ake%20Ngiamsanguan%20via%20iStock.jpg)
/Salesforce%20Inc%20HQ%20building-by%20JHVEPhoto%20via%20Shutterstock.jpg)
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)